This Biotech Fund Sold $8 Million, Yet Remains Bullish on Terns
A biotech fund reduced its Terns Pharmaceuticals position by about $8 million last quarter. Despite the sale, the the...
Budget slip-ups can silently erode savings. Learn Ways Budgeting Errors Drain Your Wallet and implement practical savings tactics.
17,919 articlesA biotech fund reduced its Terns Pharmaceuticals position by about $8 million last quarter. Despite the sale, the the...
Investors piled into Nextpower after strong 2026 results and a strategic acquisition. This article breaks down the ca...
Bitcoin sits at a crossroads as whales accumulate and policy debates heat up. This piece breaks down how many BTC cou...
China’s domestic auto market is feeling the squeeze even as exporters push ahead. Nio sits at a crossroads where poli...
Meta is testing a bold cloud strategy that could reshape its growth trajectory. This article breaks down how leasing ...
As AI infrastructure expands, CoreWeave sits at a pivotal point. This guide identifies three key risks investors shou...
Tesla’s foray into robotics and AI promises upside, but it also introduces new risks for shareholders. This guide bre...
Two early leaders in the electric air taxi race collide with a policy signal that could tilt the field. This analysis...
Traders are increasingly turning to covered calls to generate income in a volatile market. One widely cited case clai...
Drones and government funding chatter are reshaping investor sentiment. Ondas is at the center of the action, with ot...
As Disney readies Toy Story 5, investors wonder if this beloved IP can spark a broader upswing. This piece breaks dow...
Paradigm just closed a $1.2B fund, signaling a bold move at the intersection of crypto and AI. This Morning Minute ex...